J&J Kenvue spinoff adds slew of banks to its initial public offering roster

Kenvue Inc., the consumer products spinoff from Johnson & Johnson JNJ, +1.00%, has grown the roster of banks underwriting its initial public offering beyond the two original leads . Goldman Sachs ...

JNJ Bought Up Biotech Stock MeiraGTx. It Sold Procept BioRobotics.

Johnson & Johnson recently increased an investment in an embattled biotech stock, and slashed a position in a maker of surgical robotics that rocketed last year. Johnson & Johnson (ticker: JNJ...

Johnson And Johnson Stock Slips After Missing The Mark For Earnings

Getty Images Key takeaways Johnson and Johnson revealed lower earnings and sales numbers than expected in Q4 2022 Even before Q4 numbers were released, JNJ started falling after a slew of new stories ...

J&J stock rises after 2023 profit view tops analyst outlook

Johnson & Johnson JNJ, -0.25% stock rose 0.9% in premarket trades on Tuesday after the drug company’s profit outlook for 2023 topped analyst estimates. J&J’s fourth-quarter profit fell 25.7% t...

3M, Lyft, Verizon, Lululemon, and More Stock Market Movers

We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. We’ve detected you are on Internet Explorer. For the best Barrons.com e...

Johnson & Johnson Might Need a Band-Aid Ahead of Earnings

Johnson & Johnson (JNJ) is expected to report its latest quarterly earnings on Tuesday before the stock market opens. The shares have been weak so far this month so let’s review the conditio...

J&J Reports Earnings Tuesday. What to Expect.

Johnson & Johnson CEO Joaquin Duato’s warning earlier this month that the outlook for 2023 remains uncertain is tempering investor expectations ahead of the company’s earnings reports on Tuesday. ...

Tesla, AT&T, Visa, Chevron, Microsoft, and More Stocks for Investors to Watch This Week

We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. We’ve detected you are on Internet Explorer. For the best Barrons.com e...

Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...

Why Pfizer Is Pulling Back on Research Into Rare Disease, Gene Therapy

Pfizer is planning to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies, the company told employees on Thursday afternoon...

The 12 Best Income Investments for 2023, According to Barron’s

While it might not be a feast now for income-oriented investors, it’s a lot better than the famine that prevailed for much of the past decade. Yields on a range of bond and bond-related investments ro...

The Best Income Investing Ideas for 2023

While it might not be a feast now for income-oriented investors, it’s a lot better than the famine that prevailed for much of the past decade. Yields on a range of bond and bond-related investments ro...

6 Defensive Healthcare Stocks for 2023

As investors face another uncertain year for public equities, large-cap healthcare stocks remain an attractive defensive play. They offer a shot at insulating capital from the downturn many still expe...

Why Atlanta Tops the Hottest 2023 Real Estate Markets

Atlanta is hot. Georgia’s capital tops the National Association of Realtors’ list of markets to watch in 2023, based on 10 metrics, including housing affordability, employment conditions, and populati...

JNJ Stock Price Analysis: Can The Share Price Reach Yearly High Before 2022?

The Healthcare industry is among the largest sectors around the globe with several companies booming in the space. Covid pandemic gave an incredible boost to these organizations. Johnson and Johnson b...

4 Advisors on Their Top Bond Buys Now

With bonds offering their juiciest yields in years, we queried some wealth management pros on where they see the best fixed-income opportunities now: David Rossmiller, Bessemer Trust: We like longer b...

Buy AbbVie Stock. The Pharma Giant Is Still Worth Owning Even as Humira Fades.

Sometimes, a single worry grows so large that it obscures all the good things happening at the same time. That’s the case with the stock of pharma giant AbbVie whose blockbuster drug Humira faces pate...

Recession-Proof Industries To Pump Up Your Portfolio

Getty Images Key takeaways As inflation continues – and the Federal Reserve hikes interest rates to fight it – a recession appears increasingly likely To compensate, many investors are looking to inve...

Why stock market investors should wait for the 10-year Treasury to ‘blink’

When a key part of the U.S. bond market starts shrugging off new Federal Reserve interest rate hikes or tough talk on inflation, it’s probably time to buy stocks, according to James Paulsen, the Leuth...

Tesla, Netflix Set to Report Earnings as Recession Talk Mounts

Procter & Gamble Netflix and Tesla highlight a busy coming week of earnings as persistent inflation and climbing interest rates stoke talk of a recession. Consumer healthcare giant Johnson & J...

Tesla, Goldman Sachs, Netflix, AT&T, and Other Stocks for Investors to Watch This Week

We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. We’ve detected you are on Internet Explorer. For the best Barrons.com e...

Stocks down, buying JNJ, AMD disappoints

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. Jobs data weighs on stocks ...

Bond Yields Are Finally Looking Attractive. What to Buy Now.

It has taken a historic selloff, but the bond rout may finally be winding down. Yields are also looking plump enough to be attractive again. A two-year Treasury now gets you 4.1%, a yield not seen sin...

Where Is the Stock Market Going? It Could Have a Messy Fall.

If 2022 were to end tomorrow, or the day after, it would enter the books as a dismal one for investors. The Dow Jones Industrial Average is down 13% year to date, the S&P 500 index is off 17%, and...

After a Brutal Bond Selloff, Opportunities Have Emerged for Income Investors

For many years, dividend stocks were one of the few places where investors could find decent yields in a world of ultralow rates. A 10-year Treasury bond was dealing out an emaciated 1.3% a year ago, ...

Johnson & Johnson Is On a Roll, and This Trade Has My Attention

Is it now time to start buying Johnson & Johnson (JNJ) ? The shares of health care giant Johnson & Johnson have been under pressure since hitting a peak of $186.69 back in late April. Those sh...

J&J Unit Tells Appeals Court Only Bankruptcy Can Settle Talc Claims

A Johnson & Johnson subsidiary urged a federal appeals court to uphold the controversial legal strategy it used to move to bankruptcy roughly 38,000 lawsuits linking its talc-based products to can...

Johnson & Johnson Is Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...

Apple is again borrowing in the debt market to raise money to reward shareholders

Apple Inc. AAPL, -0.62% is again planning to issue debt to reward its shareholders by buying back its own shares and paying dividends, according to a regulatory filing. The iPhone maker is planning a ...

Apple Borrows Money to Buy Back Stock. What That May Say About the Bond Market.

Text size A new Apple store in London, shown in late July. Dan Kitwood/Getty Images Apple is gearing up for a four-part bond sale to fund stock buybacks. Apple (ticker: AAPL ) is planning to use the p...

9 Dividend Aristocrat Stocks That Could Ride Out a Recession

Although Hormel shares are down this year, the company is among nine Dividend Aristocrats that figure to show some resilience if a recession comes to pass. Michael Edwards/Dreamstime.com Text size Wit...

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...